Prelude Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Prelude Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$584K	Buy	+46,070	New	+$523K	0.04%	452
2025 Q4	–	Sell	-33,037	Closed	-$396K	–	1485
2025 Q3	$396K	Buy	+33,037	New	+$348K	0.03%	588
2023 Q1	–	Sell	-15,353	Closed	-$90.4K	–	1383
2022 Q4	$90.4K	Buy	15,353 +143	+0.9%	+$483	﹤0.01%	1088
2022 Q3	$49K	Sell	15,210 -1,090	-7%	-$4.36K	﹤0.01%	1232
2022 Q2	$73K	Buy	+16,300	New	+$65K	﹤0.01%	1456

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Prelude Capital Management's ORIC Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Oric Pharmaceuticals (ORIC) in Q1 2026: 46,070 shares worth $584K. The stake represents 0.04% of the portfolio and ranks #452 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in ORIC as recently as Q3 2025.

Prelude Capital Management first reported a position in ORIC in Q2 2022 and has held it in 5 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Prelude Capital Management held 46,070 shares of Oric Pharmaceuticals worth $584K as of Q1 2026.
Oric Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
Oric Pharmaceuticals made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #452 holding.
Prelude Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.